Affinity Asset Advisors, LLC - 22 Jan 2026 SCHEDULE 13G/A Report for Karyopharm Therapeutics Inc. Common Stock, $0.0001 par value per share (KPTI)

Filing Manager
Affinity Asset Advisors, LLC
Reporting Manager
Affinity Asset Advisors, LLC
Security
Karyopharm Therapeutics Inc. Common Stock, $0.0001 par value per share
Symbol
KPTI
Shares outstanding
19,919,674 shares
Disclosed Ownership
1,713,092 shares
Ownership
8.6%
Form type
SCHEDULE 13G/A
Filing time
29 Jan 2026, 21:32:49 UTC
Date of event
22 Jan 2026
Previous filing
10 Apr 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Affinity Asset Advisors, LLC disclosed 8.6% ownership in Karyopharm Therapeutics Inc. Common Stock, $0.0001 par value per share (KPTI) on 22 Jan 2026."

Quick Takeaways

  • Affinity Asset Advisors, LLC filed SCHEDULE 13G/A for Karyopharm Therapeutics Inc. Common Stock, $0.0001 par value per share (KPTI).
  • Disclosed ownership: 8.6%.
  • Date of event: 22 Jan 2026.

What Changed

  • Previous schedule filing date: 10 Apr 2025.
  • Current filing was accepted on 29 Jan 2026, 21:32.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (2)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Affinity Asset Advisors, LLC 8.6% 1,713,092 1,713,092 0 /s/ Andrew Weinstein Andrew Weinstein, Chief Financial Officer and Chief Compliance Officer
Michael Cho 8.6% 1,713,092 1,713,092 0 /s/ Michael Cho Michael Cho, Self

Sponsored